Zotatifin is under clinical development by EFFECTOR Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zotatifin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zotatifin overview

Zotatifin (eFT-226) is under development for the treatment of solid tumors including non -small cell lung cancer, hepatocellular carcinoma, triple negative breast cancer, ER positive breast cancer, colorectal cancer, diffuse large B-cell lymphoma and coronavirus disease 2019 (COVID-19). It acts by targeting eIF4A (eukaryotic initiation factor-4A). It was also under development for the treatment of acute myelocytic leukemia (AML, acute myeloblastic leukemia), lymphoma and Burkitt lymphoma. It is administered through intravenous route.

It was under development for the treatment of gastric cancer, pancreatic adenocarcinoma.

EFFECTOR Therapeutics overview

eFFECTOR Therapeutics is a biopharmaceutical company that discovers and develops selective translation regulators (STRIs) for the treatment of cancer. It is investigating its lead product candidate Tomivosertib, an oral small molecule inhibitor of MNK in combination with inhibitors of PD-1 and programmed cell death ligand 1 (PD-L1) to treat metastatic non-small cell lung cancer (NSCLC) and solid tumors. The company is also evaluating Zotatifin, an antiviral agent against estrogen receptor (ER) positive breast cancer, KRAS mutant NSCLC, solid tumors, and SARS-CoV-2; and eIF4Ei for solid tumors. Its compounds focuses on restoring the translational control of processes by preserving normal cell function. eFFECTOR Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Zotatifin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.